Manning & Napier Advisors LLC raised its position in Sanofi (NYSE:SNY) by 0.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 244,412 shares of the company’s stock after buying an additional 130 shares during the period. Manning & Napier Advisors LLC’s holdings in Sanofi were worth $11,709,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. TNB Financial purchased a new stake in Sanofi during the first quarter valued at $1,329,000. Capstone Asset Management Co. raised its stake in Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock valued at $3,719,000 after buying an additional 4,635 shares during the period. Gradient Investments LLC raised its stake in Sanofi by 15,470.7% in the first quarter. Gradient Investments LLC now owns 6,384 shares of the company’s stock valued at $289,000 after buying an additional 6,343 shares during the period. E&G Advisors LP raised its stake in Sanofi by 9.9% in the first quarter. E&G Advisors LP now owns 23,125 shares of the company’s stock valued at $1,046,000 after buying an additional 2,075 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in Sanofi by 126.0% in the first quarter. Quadrant Capital Group LLC now owns 5,525 shares of the company’s stock valued at $242,000 after buying an additional 3,080 shares during the period. 9.96% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sanofi (NYSE SNY) opened at 47.75 on Thursday. The firm has a market cap of $119.92 billion, a price-to-earnings ratio of 11.28 and a beta of 0.88. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The company’s 50 day moving average price is $48.08 and its 200-day moving average price is $46.05.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.74. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. Equities analysts expect that Sanofi will post $3.26 EPS for the current fiscal year.
SNY has been the topic of several research reports. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a report on Thursday, April 20th. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Berenberg Bank lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Finally, BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.